PTSD Susceptibility and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Reviewed by ExomeDNA Editorial Process · [/methodology/editorial-process]
Last reviewed: 2026-05-29
Disclaimer: This content is educational and informational. For health decisions, consult a clinician.
Post-traumatic stress disorder (PTSD) is a psychiatric condition that can develop following exposure to a traumatic event, involving persistent changes in fear memory processing, stress-response signaling, and emotional regulation. Genome-wide association studies across multiple ancestries and veteran cohorts have identified variants near genes including FES, ADCY8, DOCK4, and CSMD1 as part of the broader genetic architecture influencing susceptibility. This page explains what that research shows, how these biological pathways function, and what population-level genetic findings mean in context.
What is PTSD?
Post-traumatic stress disorder is a psychiatric condition that can emerge after a person experiences or witnesses a traumatic event. It is characterized by intrusive memories, avoidance of trauma-related cues, negative shifts in mood and cognition, and heightened arousal. PTSD is not a sign of weakness — it reflects measurable changes in stress-response circuits and fear memory systems. Prevalence estimates vary by population and trauma type, and not everyone who experiences trauma develops the condition.
Genetics is one of many factors that shape individual vulnerability. Heritability estimates from twin studies place the genetic contribution to PTSD susceptibility in the range of roughly 30–40%, which means that life experience, trauma severity, social support, and other non-genetic factors account for the larger share of risk. Genome-wide association research has been conducted across military veteran cohorts, civilian trauma-exposed samples, and multi-ancestry international consortia, collectively spanning hundreds of thousands of participants and producing a growing list of candidate loci.
The genetics behind PTSD
Large-scale genome-wide association studies have identified multiple genomic regions associated with PTSD susceptibility. Among the strongest signals, the locus near FES (feline sarcoma proto-oncogene, a non-receptor tyrosine kinase involved in immune signaling and neural development) has emerged with notable statistical support across studies[1][5]. While FES is best known for roles in hematopoiesis, its expression in the central nervous system and involvement in synaptic signaling pathways makes it a biologically plausible candidate for stress-response phenotypes.
ADCY8 encodes adenylate cyclase type 8, a calcium/calmodulin-stimulated enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP) — a critical second messenger in the HPA (hypothalamic-pituitary-adrenal) axis and in fear memory consolidation within the amygdala. Variants near ADCY8 have appeared in PTSD association signals across multiple study cohorts[2][3], consistent with its mechanistic role in regulating the cAMP cascade that underlies fear learning and extinction.
DOCK4 (dedicator of cytokinesis 4) is a guanine nucleotide exchange factor expressed in the brain, where it regulates dendritic spine morphology and synaptic plasticity. Its appearance among PTSD-associated loci aligns with evidence that structural synaptic changes accompany both trauma exposure and the persistent hyperarousal and re-experiencing symptoms characteristic of PTSD[4][6].
CSMD1 (CUB and Sushi multiple domains 1) encodes a large complement-regulatory protein expressed predominantly in the brain. Variants in CSMD1 have been associated with several psychiatric phenotypes, and its role in neuroinflammatory signaling and complement cascade regulation may connect to the immune and inflammatory components of stress response[7].
Additional loci near ANKRD55, CCKAR (cholecystokinin A receptor — a neuropeptide receptor implicated in anxiety and fear), and ELFN1 (a synaptic organizing protein at inhibitory synapses) round out a picture of PTSD susceptibility as a polygenic condition involving convergent pathways: HPA axis regulation, fear circuit plasticity, GABAergic inhibitory tone, and neuroimmune signaling.
International meta-analysis (2019): A multi-ancestry GWAS spanning more than 30 cohorts and over 23,000 PTSD cases identified sex- and ancestry-specific genetic risk loci, underscoring that the genetic architecture of PTSD is not uniform across populations (Nievergelt 2019[6]).
Million Veteran Program (2021): A genome-wide analysis of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program identified novel loci associated with specific PTSD symptom clusters — intrusion, avoidance, negative cognition, and hyperarousal — pointing to partially distinct genetic architectures for different aspects of the condition (Stein 2021[8]).
What the research says
The published literature on PTSD genetics spans nearly a decade of progressively larger studies, from early candidate-gene efforts to large multi-cohort meta-analyses.
Early work by Xie and colleagues (2013) in a predominantly European-ancestry cohort identified initial GWAS signals for PTSD susceptibility, providing a foundation for subsequent replication efforts[1]. Wolf and colleagues (2014) extended GWAS methodology to dissociative symptoms in trauma-exposed samples, capturing phenotypic heterogeneity within the PTSD spectrum[2].
Nievergelt and colleagues (2015) examined combat-exposed U.S. Marines across multiple ancestries, highlighting that genomic risk factors for stress vulnerability and resilience may differ by ancestry — an important caveat for interpreting any single-population finding[3]. Ashley-Koch and colleagues (2015) conducted a GWAS in Iraq- and Afghanistan-era veterans, identifying loci that converge with independent signals from civilian cohorts[4].
Stein and colleagues (2016) used two cohorts of U.S. Army soldiers to perform one of the first military-focused GWAS for PTSD, establishing that common genetic variants contribute meaningfully to susceptibility in high-trauma-exposure populations[5]. The landmark 2019 international meta-analysis led by Nievergelt and colleagues demonstrated sex-stratified effects, with some loci showing stronger association in women than in men, consistent with the higher clinical prevalence of PTSD in women following equivalent trauma exposure[6].
Shen and colleagues (2020) extended polygenic prediction approaches to PTSD alongside depression and suicidal ideation in a Peruvian cohort, illustrating cross-population transferability and the shared genetic architecture between PTSD and mood disorders[7]. The Million Veteran Program analysis by Stein and colleagues (2021) leveraged one of the largest biobank resources available to interrogate symptom-level genetic architecture, connecting specific loci to intrusion versus avoidance phenotypes[8].
Swart and colleagues (2021) examined a South African population, identifying associations between PTSD polygenic risk and metabolic syndrome outcomes — an important finding connecting psychiatric genetic risk to broader cardiometabolic health trajectories[9]. Maihofer and colleagues (2022) enhanced discovery power by integrating quantitative phenotypes and trauma exposure data with standard GWAS, demonstrating that more nuanced phenotyping improves locus discovery[10]. Finally, Zhou and colleagues (2023) investigated shared genetic architecture between PTSD and gastrointestinal tract disorders using cross-trait analysis, identifying overlapping loci that may reflect bidirectional gut-brain pathway involvement in stress response[11].
Collectively, this body of research establishes PTSD susceptibility as robustly polygenic, with contributing loci spanning stress-response, fear memory, GABAergic, and neuroimmune pathways.
How PTSD affects you
PTSD involves changes across multiple biological systems that persist long after the traumatic event. The HPA axis — the hormonal cascade linking the hypothalamus, pituitary gland, and adrenal glands — typically shows dysregulated cortisol dynamics in people with PTSD, with some studies reporting blunted basal cortisol and others reporting sensitized stress reactivity. Genes like ADCY8, which regulate the cAMP signaling downstream of stress hormones, sit at the molecular intersection of this dysregulation.
Fear memory circuits centered on the amygdala, hippocampus, and prefrontal cortex are also affected. In PTSD, fear memories encoded during trauma may be over-consolidated and resistant to extinction — the normal process by which fear responses are dampened when the threatening stimulus no longer predicts danger. Synaptic plasticity genes such as DOCK4 and ELFN1 influence the structural and functional properties of these circuits.
Neuroimmune contributions are increasingly recognized. CSMD1's role in complement regulation places neuroinflammatory signaling within the PTSD genetic architecture, consistent with studies showing elevated inflammatory markers in people with the condition.
It is important to emphasize that carrying common genetic variants associated with elevated PTSD susceptibility does not mean a person will develop PTSD. These are population-level associations derived from large studies. The majority of people exposed to trauma — even those carrying susceptibility variants — do not develop persistent PTSD. Protective factors including social support, prior resilience experiences, access to timely care, and other genetic and epigenetic influences also shape outcomes.
Working with your PTSD profile
Understanding the genetic factors associated with PTSD susceptibility can provide context for how stress-response biology varies across individuals. Several evidence-based approaches are well-supported for those navigating trauma histories or managing elevated stress responses.
Psychotherapy — particularly trauma-focused cognitive behavioral therapy (TF-CBT) and eye movement desensitization and reprocessing (EMDR) — has the strongest evidence base for PTSD treatment. These approaches directly engage fear memory reconsolidation and extinction circuits, the same pathways implicated in the genetic architecture described above.
Physical activity has been shown to support HPA axis regulation and promote neuroplasticity in stress-response circuits. Sleep quality is also strongly linked to fear memory consolidation and extinction, making sleep hygiene an important consideration.
For anyone experiencing PTSD symptoms or navigating trauma history, consultation with a licensed mental health clinician is the appropriate starting point. Genetic susceptibility information provides biological context — it does not substitute for clinical assessment or treatment planning.
Related traits and genes
PTSD susceptibility shares genetic architecture with several related traits. Common variant overlap has been documented with major depression, generalized anxiety disorder, and bipolar disorder — reflecting the broad stress-response and fear-circuit pathways that cut across psychiatric phenotypes. The loci near ADCY8 and CCKAR are particularly relevant to anxiety-adjacent phenotypes.
The DOCK4 locus has also appeared in autism spectrum disorder GWAS signals, consistent with synaptic organizing proteins influencing a range of neurodevelopmental and stress-response outcomes.
For readers interested in related content, the PTSD Co-occurring Depression Risk and Generalized Anxiety Susceptibility pages explore overlapping genetic pathways. Cross-category connections include HPA Axis Cortisol Response and Inflammatory Marker Levels, which share biological pathway overlap with PTSD susceptibility. The gene page for FES covers the top-ranked locus in detail.
Internal links: PTSD Co-occurring Depression Risk · Generalized Anxiety Susceptibility · HPA Axis Cortisol Response · Inflammatory Marker Levels · FES gene page
Frequently asked questions
Does having genetic variants associated with PTSD mean I will develop it?
No. Genetic variants associated with PTSD susceptibility reflect population-level patterns from large research studies. The presence of susceptibility variants describes a statistical tendency across groups, not an individual outcome. Most people who experience trauma, including those carrying susceptibility variants, do not develop persistent PTSD. Non-genetic factors — including trauma severity, social support, prior experience, and access to care — account for the majority of individual variation in outcomes.
Are PTSD susceptibility variants the same across different populations?
Not entirely. Research has found both sex-specific and ancestry-specific genetic risk loci for PTSD. An international meta-analysis identified loci with stronger effects in women than in men, consistent with observed differences in clinical prevalence. Studies in European, African, Hispanic, and South Asian ancestries have found some overlapping and some distinct signals, which means findings from one population may not fully transfer to another.
What biological pathways are involved in the genetics of PTSD?
The best-supported pathways implicate HPA axis regulation (cyclic AMP signaling via ADCY8), fear memory consolidation and synaptic plasticity (DOCK4, ELFN1), GABAergic inhibitory tone (GABBR2), complement-mediated neuroimmune signaling (CSMD1), and neuropeptide receptor systems (CCKAR). These are not independent pathways — they interact within the broader stress-response and fear-circuit architecture of the brain.
How many genetic loci are currently associated with PTSD?
The number of identified loci continues to grow as sample sizes increase. Early studies identified single genome-wide significant loci; subsequent multi-cohort meta-analyses have identified multiple independent signals. The Million Veteran Program analysis extended discovery to symptom-level subdomains, identifying distinct loci associated with intrusion, avoidance, negative cognition, and hyperarousal clusters. Research in this area remains active and the genetic map of PTSD susceptibility is not yet complete.
Does PTSD share genetic factors with other conditions?
Yes. Cross-trait analyses have found overlapping genetic architecture between PTSD and major depression, generalized anxiety disorder, and gastrointestinal tract disorders. A 2020 polygenic analysis found correlated genetic signals across PTSD, depression, and suicidal ideation. A 2023 cross-trait study identified shared loci between PTSD and gastrointestinal conditions, consistent with bidirectional gut-brain pathway involvement in chronic stress response. These overlaps suggest shared biological mechanisms rather than condition-specific pathways for a subset of loci.
What does a "featured" interest tier mean for this trait?
The featured tier designation reflects consumer relevance, research depth, and the actionability of the biological context. PTSD susceptibility ranks highly on all three dimensions: it is a condition of significant public health importance, supported by a substantial body of GWAS research spanning over a decade, and the biological pathways implicated connect to evidence-based interventions. This page presents the broad multi-study genetic architecture; a companion page addresses PTSD co-occurring with depression specifically.
References
- Xie P et al. (2013). Genome-wide association study identifies new susceptibility loci for posttraumatic stress disorder. Biol Psychiatry. PMID: 23726511
- Wolf EJ et al. (2014). A genome-wide association study of clinical symptoms of dissociation in a trauma-exposed sample. Depress Anxiety. PMID: 24677629
- Nievergelt CM et al. (2015). Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology. PMID: 25456346
- Ashley-Koch AE et al. (2015). Genome-wide association study of posttraumatic stress disorder in a cohort of Iraq-Afghanistan era veterans. J Affect Disord. PMID: 26114229
- Stein MB et al. (2016). Genome-wide Association Studies of Posttraumatic Stress Disorder in 2 Cohorts of US Army Soldiers. JAMA Psychiatry. PMID: 27167565
- Nievergelt CM et al. (2019). International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun. PMID: 31594949
- Shen H et al. (2020). Polygenic prediction and GWAS of depression, PTSD, and suicidal ideation/self-harm in a Peruvian cohort. Neuropsychopharmacology. PMID: 31926482
- Stein MB et al. (2021). Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program. Nat Genet. PMID: 33510476
- Swart PC et al. (2021). A Genome-Wide Association Study and Polygenic Risk Score Analysis of Posttraumatic Stress Disorder and Metabolic Syndrome in a South African Population. Front Neurosci. PMID: 34177453
- Maihofer AX et al. (2022). Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information. Biol Psychiatry. PMID: 34865855
- Zhou Y et al. (2023). Investigating the shared genetic architecture of post-traumatic stress disorder and gastrointestinal tract disorders: a genome-wide cross-trait analysis. Psychol Med. PMID: 37218628
Data sources: GWAS Catalog (NHGRI-EBI, accessed 2026-05-29) · Open Targets Platform (CC0 1.0, accessed 2026-05-29) · ClinVar (NCBI, accessed 2026-05-29; entries at ≥2-star review status) · ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)
By the ExomeDNA Research Team
FDA wellness compliance statement: This content is intended for educational and informational purposes only. ExomeDNA's genetic reports are wellness products, not clinical tools, and are not substitutes for professional health guidance. Genetic variants discussed reflect population-level associations from published research. Individual genetic results should be interpreted with the guidance of a qualified healthcare provider.